National Registries of Systemic Treatment for Psoriasis and the European 'Psonet' Initiative

被引:44
作者
Lecluse, L. L. A. [1 ]
Naldi, L. [2 ]
Stern, R. S. [3 ]
Spuls, P. I. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1100 DE Amsterdam, Netherlands
[2] Osped Riuniti Bergamo, Ctr Studi GISED, I-24100 Bergamo, Italy
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
关键词
Psoriasis registries; Treatment outcome; Systemic therapy; safety; THERAPY; ETANERCEPT; LIFE; NEED;
D O I
10.1159/000183757
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
About 11 million people suffer from psoriasis in Europe. This chronic condition may have a dramatic impact on quality of life. About 20% of patients may need systemic treatment to effectively control their disease activity. The introduction of biological agents greatly increased the options of systemic therapies for psoriasis. However, clinical experience with newer systemic therapies is relatively limited, and available data are mostly derived from short-term phase III trials. Except for PUVA and ciclosporin, long-term safety data from formal postmarketing studies are also largely lacking conventional treatment options. Registries provide one mechanism to monitor the long-term safety and effectiveness of treatment in the 'natural environment'. Several European countries have established registries to collect data on systemic psoriasis treatment. Even though different in some aspects of study design and monitoring, the registries share a number of common features: they include all the biological drugs and sometimes all the licensed systemic agents for psoriasis, and they observe the patients for a defined period of time irrespective of the drug given. Combining the results from these registries would increase their power and impact. We are developing an international collaboration called 'Psonet' that will perform a joint analysis of data from 9 individual national psoriasis registries. Copyright (C) 2008 S. Karger AG, Basel
引用
收藏
页码:347 / 356
页数:10
相关论文
共 18 条
[1]  
*AHRQ, SUMM REG EV PAT OUTC
[2]   Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice [J].
Berends, Maartje A. M. ;
Driessen, Rieke J. B. ;
Langewouters, Annechien M. G. ;
Boezeman, Jan B. ;
Van de Kerkhof, Peter C. M. ;
De Jong, Elke M. G. J. .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2007, 18 (02) :76-83
[3]   Cross sectional survey of multicentre clinical databases in the United Kingdom [J].
Black, N ;
Barker, M ;
Payne, M .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7454) :1478-1481
[4]   Initial experience with routine administration of etanercept in psoriasis [J].
de Groot, M. ;
Appelman, M. ;
Spuls, P. I. ;
de Rie, M. A. ;
Bos, J. D. .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (04) :808-814
[5]  
DRIESSEN RJ, 2007, NED TIJDSCHR DERMATO, V17, P162
[6]   Psoriasis clinical registries, genetics, and genomics [J].
Elder, JT .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 :106-107
[7]  
Farber EM., 1998, PSORIASIS-TARGETS TH, P107
[8]  
*GRUPP LAV PSOC, TRATT PSOR FARM SIST
[9]   'Biologics': a clinically meaningless term [J].
Katz, KA .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (05) :809-812
[10]  
Krueger G, 2001, ARCH DERMATOL, V137, P280